US0673831097
BARD C R INC
NYSE:BCR (12/28/2017, 7:18:13 PM)
After market: 331.97 +0.73 (+0.22%)331.24
-1.95 (-0.59%)
C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems etc.
BARD C R INC
730 CENTRAL AVE
MURRAY HILL NJ 07974
P: 908-277-8000
CEO: Timothy M. Ring
The growth of Amazon stock could be sustained for years if the company continues its foray into the health care industry, where it could be a disrupter.
Currently, CR Bard Inc (NYSE:BCR) has a Strong Buy using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BCR has had from Portfolio Grader for 3 months.
Here you can normally see the latest stock twits on BCR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: